沙库巴曲缬沙坦钠治疗急性心肌梗死后心力衰竭效果观察

doi:10.3969/j.issn.1007-3205.2021.10.002

摘要/Abstract

摘要： 目的观察沙库巴曲缬沙坦钠治疗急性心肌梗死后心力衰竭的效果，使其更好改善预后。
方法纳入急性心肌梗死伴有心力衰竭且经皮冠状动脉介入治疗患者86例，据临床治疗方法不同分为对照组（贝那普利）和观察组（沙库巴曲缬沙坦钠），每组43例。比较2组术后3个月心脏超声指标［左心室收缩末期容积（left ventricular end-systolic volume，LVESV）、左心室舒张末期容积（left ventricular end-diastolic volume，LVEDD）、左心室射血分数（left ventricular ejection fraction LVEF）、每搏输出量（stroke volume,SV）］、血清学炎症因子变化［超敏C反应蛋白［（high sensitivity C-reactive protein，hs-CRP）和白细胞介素6（interleukin-6，IL-6）］、N末端B型利钠肽原（N-terminalpro-B-type natriuretic peptide,NT-proBNP）、6 min步行实验、不良反应发生率、预后及转归等。
结果治疗后，2组LVESV、LVEDD低于治疗前，LVEF、SV高于治疗前，观察组LVESV、LVEDD低于对照组，LVEF、SV高于对照组，差异有统计学意义（P＜0.05）。2组hs-CRP、IL-6、NT-proBNP水平低于治疗前，观察组hs-CRP、IL-6、NT-proBNP水平低于对照组，差异有统计学意义（P＜0.05）。2组低血压、高钾血症、肾功能不全不良反应发生率差异无统计学意义（P＞0.05）。2组再发心肌梗死、室性心动过速/频发室性期前收缩、心源性猝死差异无统计学意义（P＞0.05）；观察组心力衰竭再住院率低于对照组，6 min步行实验长于对照组，差异有统计学意义（P＜0.05）。
结论与贝那普利相比，沙库巴曲缬沙坦可改善心肌梗死后心力衰竭左心室心功能、左心室重塑，增强其活动耐量，降低心力衰竭再住院率，但并不增加不良反应及不良心血管事件发生率。

关键词: 心肌梗死, 心力衰竭, 沙库巴曲缬沙坦

Abstract: Objective To observe the effect of Sacubitril/valsartan, in comparison to benazepril, in the treatment of patients with heart failure after acute myocardial infarction(AMI), so as to improve the prognosis.
Methods A total of 86 patients with heart failure after AMI undergoing percutaneous coronary intervention(PCI) were selected. According to different treatment methods, they were divided into control group(benazepril) and observation group(Sacubitril/valsartan), with 43 cases in each group. At 3 months after operation, echocardiographic data［left ventricular end-systolic volume(LVESV), left ventricular end-diastolic volume(LVEDV), left ventricular ejection fraction(LVEF), stroke volume(SV)］, serum inflammatory factors［high-sensitivity C-reactive protein(hs-CRP), interleukin-6(IL-6)］, N-terminal pro-B-type natriuretic peptide(NT-proBNP), 6-min walking test, adverse reactions, prognosis and outcome were compared.
Results After treatment, LVESV and LVEDD in the two groups were lower than those before treatment, and LVEF and SV were higher than those before treatment. However, LVESV and LVEDD in the observation group were lower than those in the control group, and LVEF and SV were higher than those in the control group, with statistically significant differences(P＜0.05). The levels of hs-CRP, IL-6 and NT-proBNP in the two groups were lower than those before treatment, which were lower in the observation group than in the control group, with statistically significant differences(P＜0.05). There was no statistically significant difference in the incidence of adverse reactions, such as hypotension, hyperkalemia and renal insufficiency between the two groups(P＞0.05). There was no statistically significant difference in recurrent myocardial infarction, ventricular tachycardia/frequent ventricular premature beats and sudden cardiac death between two groups(P＞0.05). The re-hospitalization rate of patients with heart failure in the observation group was lower than that in the control group, and the 6-min walking test in the observation group was longer than that in the control group, with statistically significant differences(P＜0.05).
Conclusion Compared with benazepril, Sacubitril/valsartan can improve left ventricular function and left ventricular remodeling in patients with heart failure after myocardial infarction, increase its activity tolerance, and reduce the rate of re-hospitalization for heart failure, but will not increase the incidence of adverse reactions and adverse cardiovascular events.

Key words: myocardial infarction, heart failure, sacubitril/valsartan

张杨春, 符金娟, 蔡琳. 沙库巴曲缬沙坦钠治疗急性心肌梗死后心力衰竭效果观察[J]. 河北医科大学学报, 2021, 42(10): 1123-1127.

ZHANG Yang-chuan, FU Jin-juan, CAI Lin. Observation on the effect of Sacubitril/valsartan in the treatment of patients with heart failure after acute myocardial infarction[J]. Journal of Hebei Medical University, 2021, 42(10): 1123-1127.

[1]	徐进林, 肖兵, 韩从华, 朱冬梅, 印章, 艾宇. 胸痛中心建设对急性ST段抬高型心肌梗死再灌注患者心功能及短期预后的影响 [J]. 河北医科大学学报, 2023, 44(9): 1022-1026.
[2]	李庆, 李彦, 廖中华, 方凯. 体外膜肺氧合联合急诊PCI抢救STEMI后心脏骤停死亡危险因素分析 [J]. 河北医科大学学报, 2023, 44(4): 412-416.
[3]	王家琦, 刘立天（综述）, 张飞飞, 齐晓勇（审校）. 心力衰竭中心肌能量代谢的研究进展 [J]. 河北医科大学学报, 2022, 43(8): 962-965.
[4]	刘志东, 王贤方, 余丽琼, 钟炜. 临床特征及实验室指标联合预测急性ST段抬高型心肌梗死患者梗死相关动脉自发再通风险的价值 [J]. 河北医科大学学报, 2022, 43(7): 754-758,780.
[5]	张文川. 铁调素/铁蛋白比值在预测维持性血液透析患者心功能的应用[J]. 河北医科大学学报, 2022, 43(5): 525-529.
[6]	孙倩, 苏艳, 张雅兰, 李晓林. 研究STEMI患者RBP4、HbA1c与miR-1-3p检测水平的诊断价值及与病情关系 [J]. 河北医科大学学报, 2022, 43(10): 1127-1132.
[7]	王亚玲, 张杨, 郭安君, 饶明月, 张晓丹, 孟建康. 心脏永久性起搏器的不同起搏部位对植入患者心功能的影响[J]. 河北医科大学学报, 2022, 43(1): 22-25,30.
[8]	张飞飞, 宋学莲, 谢悦陶, 刘立天, 党懿, 齐晓勇. 直接经皮冠状动脉介入治疗应用血栓抽吸对STEMI患者心肌灌注及临床预后的影响[J]. 河北医科大学学报, 2021, 42(7): 770-778.
[9]	陈宇娇, 刘昕, 薛娜, 穆维娜. 经胸实时三维超声心动图对比研究不同梗死部位缺血性二尖瓣反流的二尖瓣构型[J]. 河北医科大学学报, 2021, 42(5): 582-586.
[10]	赵洁, 李淑英, 张英, 单伟超, 韩冷, 丁振江. 低密度脂蛋白胆固醇与中青年冠心病患者冠状动脉病变程度的相关性分析[J]. 河北医科大学学报, 2021, 42(3): 278-280,285.
[11]	黄玲芳, 周松, 刘黎洁, 狄宁宁, 高艳周. 环磷腺苷葡胺结合磷酸肌酸钠治疗急性心肌梗死伴心力衰竭患者的效果及对CPP、sNEP表达的影响[J]. 河北医科大学学报, 2021, 42(12): 1382-1386.
[12]	李欣悦, 耿巍, 刘素芬, 田祥. 高敏肌钙蛋白T对慢性肾衰竭非透析患者急性心肌梗死的诊断价值[J]. 河北医科大学学报, 2021, 42(1): 12-16.
[13]	赵甲彧1，刘雅婷2，朱男1，张芳2. TIMI心肌灌注帧数在STEMI患者PCI术后MVO评价中的应用[J]. 河北医科大学学报, 2020, 41(9): 1011-1015,1064.
[14]	宋博超, 汪雁博, 郝国贞, 范卫泽, 姜云发, 谷新顺. 静脉应用rhBNP对急性前壁心肌梗死合并糖尿病患者肾功能的影响[J]. 河北医科大学学报, 2020, 41(8): 873-877,914.
[15]	孟海云, 谷新顺, 张旗. 急性心肌梗死患者丁酰胆碱酯酶活性与炎症因子、预后的关系分析[J]. 河北医科大学学报, 2020, 41(8): 878-881,887.

沙库巴曲缬沙坦钠治疗急性心肌梗死后心力衰竭效果观察

Observation on the effect of Sacubitril/valsartan in the treatment of patients with heart failure after acute myocardial infarction

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价